CS MEDICA provides patent update
CS MEDICA (”CS MEDICA” or the ”Company”) announces today that the Company has completed all PCT continuation patents, in total 7 patents applications covering 11 products.
CS MEDICA strives toward granting patent acceptance on all present and future treatment products. All CS MEDICA’s treatment products (topical and oral) as of today are patented in accordance with PCT (Patent Cooperation Treaty), covering 153 nations across the globe. The Company currently has seven proceeding patents that are filed and pending. The 15th of September 2022 the USA national patent application on Arthritis & Psoriasis Gel have been published.
All patent applications are continuations of the patent application earlier submitted. The status of the patent applications are shown in below table:
The patent applications includes the following phases:
- Phase I (PRI): DK application (PRI)
- Phase II (PCT): continuations of the DK application to the PCT application, covering 153 nations across the globe
- Phase III (ORD): continuations of the PCT application to national applications
After the PCT (phase II), the patents will enter national phases (phase III) where CS MEDICA needs to determine in which countries and/or regions the Company intend to pursue patents. It is the current strategy to extend this protection in the US, China, Europe, Australia, New Zealand, Japan, India, Canada, Israel, and South Korea.
The published patents of continuations of patent application can be found on the webpage patentscope.wipo.int by searching for “CS Medica and Henriksen” or via this link.
The patents are intended to strengthen the protection of the Company’s products. If granted, the patents will protect the technology til 2039 (patent filed in 2019) and 2041 (patents filed in 2021).
With this patent update , CS MEDICA are now finalising the strategic objectives covering patents for the second half of 2021/2022.
For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.
The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.